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Summary Cancer stem cells (CSC) are chemoresistant and
implicated in tumor recurrence, metastasis and high patient
mortality; thus substances impairing CSC activity, could be
invaluable as novel cancer therapeutics. We previously
showed that CAPE (caffeic acid phenethyl ester), a compo-
nent of propolis, a honeybee product, inhibits growth of
MDA-MB-231 (MDA-231) cells, mdr gene expression,
NF-κB, EGFR, and VEGF. We hypothesized that CAPE also
acts by interfering with CSC-mediated effects. We isolated
breast CSC (bCSC) from MDA-231 cells, a model of human
triple-negative breast cancer, and mouse xenografts. bCSC
grow as mammospheres (MMS) and when dissociated into
single cells, form MMS again, a sign of self-renewal. bCSC
exhibited the characteristic CD44+/CD24-/low phenotype and
generated progenitors in the presence of serum, a CSC trait
responsible for regenerating tumor mass. CAPE caused
dose-dependent bCSC self-renewal inhibition and progenitor
formation. Clonal growth on soft agar was inhibited dose-
dependently, but apoptosis was not induced as determined by
Annexin-V/PI assay. Instead, bCSC were noted to signifi-
cantly progress from a quiescent cell cycle state in G0/G1
(82%), S phase (12%) to a cycling state with an increase in S
phase (41%) and subsequent decrease in G0/G1 (54%).
Treatment of bCSC with CAPE (4.5-days) decreased CD44
levels by 95%, while another cell population containing
10-100-fold lower CD44 content concurrently increased.
Results suggest that CAPE causes pronounced changes
in bCSC characteristics manifested by inhibition of self
renewal, progenitor formation, clonal growth in soft agar,
and concurrent significant decrease in CD44 content, all
signs of decreased malignancy potential.
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Abbreviations
bCSC Breast cancer stem cells
CAPE Caffeic acid phenethyl ester
HA Hyaluronan
LB-15mm Leibowitz-15 medium for MMS




TNBC Triple negative breast cancer
ULA Ultra low attachment
Introduction
A subset of cells in tumors called cancer stem cells (CSCs)
or cancer initiating cells are found in many solid tumor
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types, including breast cancer and can give rise to the
differentiated cells that make up the tumor bulk [1–4].
Suspension sphere cultures have been used to enrich for
and characterize stem/progenitor cells from primary breast
and glioblastomic tissues [5–7]. This process is thought to
simulate the events of tissue regeneration and maintenance
from cells that survive suspension conditions. In human
breast cancers, these tumorigenic breast cancer stem cells
(bCSC) are enriched in cells with a CD44+/CD24-/low/ESA+
phenotype [1]. CD44+/CD24-/low/ESA+ cells exhibit prop-
erties of self-renewal in vitro, form tumors from very few
cells, divide slowly, and are selectively resistant to
chemotherapy, all of which are hallmarks of cancer stem
cells [8].
CD44 acts as a receptor for hyaluronan. Hyaluronan
(HA) is a high molecular weight glycosaminoglycan,
extracellular matrix component essential for proper cell
growth, organ structural stability, and tissue organization
[9]. HA acts through CD44, its principal receptor, and
RHAMM (receptor for HA mediated motility) to regulate
cell proliferation and movement [10]. Many of the
downstream pathways following CD44 activation become
deregulated in cancer, leading to tumor growth, progression
and metastasis [11–13]. Changes in both CD44 and HA
expression have been widely observed in tumors from
cancer patients and occur in animal models of tumor growth
[14]. During carcinogenesis, expression of the standard
form of CD44 is upregulated in certain cancers. Interfer-
ence with the CD44-HA interaction by either targeting
drugs to CD44, to the HA matrix or interfering with HA
matrix-CD44 interactions are viable strategies for cancer
treatments [15–17].
Caffeic acid phenethyl ester (CAPE) is one of the main
medicinal components of propolis, a honeybee-derived
natural product. CAPE possesses important biological
activities, including antibacterial, antiviral, antioxidant,
anti-inflammatory, and anti-cancer [18–21]. CAPE inhibits
nuclear factor kappa B (NF-κB) and induces apoptosis [22–
24]. CAPE’s anticancer effects have been demonstrated in a
number of cancer models [25–34], including our data on
breast cancer [35–39]. We have previously shown that
CAPE inhibits mdr gene expression, NF-κB, EGFR, and
VEGF. CAPE inhibits growth of MCF-7 and MDA-231
cells in vitro and in vivo; in particular, CAPE optimally
inhibited MDA-231 xenografts at even lower doses than
those required for inhibition of MCF-7-induced tumors
([36], Wu J, Omene C et al., manuscript submitted).
In this study, we investigated the effect of CAPE on
breast cancer stem cells derived from the triple negative
breast cancer (TNBC) model, MDA-231 cells, an aggres-
sive subtype of breast cancer and analyzed the effects on
bCSC’s self renewal, progenitor formation, and the CD44
cell marker phenotype, cell cycle, and apoptosis.
Materials and methods
Mammosphere culture and bCSC isolation
MDA-MB-231 (MDA-231) cells were cultured in Leibovitz
L-15 medium (LB-15) (Cellgro, Manassas, VA) supple-
mented with 5% FBS (Cellgro, Manassas, VA). Floating
cells were collected and cultured in six-well Ultra Low
Attachment (ULA) plates (Corning, NY) using 3×104 cells
per well in 3 ml serum-free mammosphere medium [LB15-
mm: LB-15 containing 1:50 B27 (Invitrogen Ltd.) and
20 ng/ml epidermal growth factor (EGF; R&D Systems,
Inc.)]. Cells were fed every 3 days and passaged using
0.05% trypsin-0.53 mmol/L EDTA-Na4. The MDA-231
cell line and cells derived from MDA-231-induced nude
mouse xenografts were cultured in LB-15 medium+5%
FBS. bCSC were grown as MMS in LB15-mm medium in
the absence of serum, as described above. MMS were used
for experiments after 4 weeks of growth in culture.
CSC surface marker characterization
Mammospheres derived from MDA-231 cells were disso-
ciated with trypsin-EDTA to form single-cell suspensions.
Cells were washed, blocked by 1X PBS in the presence of
2% BSA and resuspended in wash buffer (106cells/100 μl).
Fluorochrome-conjugated monoclonal antibodies (BD Bio-
science) against human CD44 (APC) and CD24 (PE) were
added to the cell suspensions according to the manufacturer
instructions and incubated at 4°C in the dark for 30–40 min.
The labeled cells were washed and fixed in PBS containing
1% paraformaldehyde before analysis by flow cytometry on
FACScalibur (Becton Dickinson).
Cell viability and apoptosis assays
Mammospheres were grown in serum-free MMS medium
(LB15-mm). Following passaging, MMS were allowed to
settle via gravity in a 15 ml centrifuge tube for 20–30 min
and the supernatant was gently discarded. After complete
removal of a supernatant, MMS were dissociated into single
cells by incubation with trypsin-EDTA at 37°C for 3 min
and light vortexing. After diluting trypsin with LB-15
medium, cells were pelleted (1,500 rpm/5 min) and
resuspended in LB15-mm. Single cell suspensions were
seeded into 6-well ULA plates (3×104/3 ml LB15-mm/
well), and CAPE (Sigma-Aldrich) in DMSO (3-μl stock
solution) or 3-μl DMSO were added/well; the latter as a
vehicle control. Equal volume of DMSO was added to
controls for a final DMSO concentration of 0.1%. After
4.5 days, MMS were collected, dissociated by trypsin-
EDTA to single cells, and cells were counted using trypan
blue exclusion assay.
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In other bCSC viability experiments, CAPE-pretreated
or untreated MMS were seeded in regular, cell adherent
96-well plates (Corning, NY), at densities of 800, 400,
200, and 100 cells/well in 200 μL of LB-15 medium
containing 5% FBS. After 6 days, 10 μl of 5 mg/ml
MTT, a tetrazolium dye colorimetric test were added into
each well and incubated for 4 h. DMSO was used to
dissolve the purple formazan crystals inside the cells. At
the end of incubation, cell viability was assessed as
indicated by the conversion of tetrazolium salts to a
colored product formazan, the concentration of which
was measured spectrophotometrically to calculate the
IC50 value.
For apoptosis experiments, 3×104/3 ml LB15-mm/well
cells were seeded and incubated with CAPE for 4.5 days.
Cells were harvested, washed twice with PBS, and
centrifuged. 1×104 cells per sample were treated with
Annexin V-FITC and propidium iodide (PI) using the
apoptosis Detection Kit (BD Bioscience Pharmingen, San
Jose, CA) according to the manufacturer’s protocol.
Annexin V-FITC and PI binding were analyzed by flow
cytometry without gating restrictions using 5,000 cells.
Data were collected using logarithmic amplification of both
the FL1 (FITC) and FL2 (PI) channels. Quadrant analysis
of co-ordinate dot plots was performed with CellQuest
software. Unstained cells were used to adjust the photo-
multiplier voltage and for compensation setting adjustment
in order to eliminate spectral overlap between the FL1 and
FL2 signals.
Cell cycle analyses
Single-cell suspension cells derived from MMS were
seeded as above and treated with either 0 μM or 40 μM
CAPE for 48 h. Samples were then collected, prepared
as single-cell suspensions, and fixed in cold 70%
ethanol for 24 h at −20°C. Fixed cells were washed
with 1XPBS and stained with propidium iodide solution
containing RNAse A at 10 μg/ml before analysis by
flow cytometry.
Clonal growth on soft agar
3×104 single-cell suspensions isolated from MDA-231’s
MMS were seeded in 6-well ULA plates in 3 ml LB-15 mm
medium and treated with different concentrations of
CAPE for 2 weeks. After treatment, MMS were collected
and dissociated to single cell suspensions. 1×104 cells were
then seeded onto soft agar for 1 week or 4 weeks in the
presence of 5% FBS and clones were counted under an
inverted microscope. Clones with ≥50 cells together are
counted as one clone. Clones did not grow in the
absence of FBS.
Results
bCSC isolation and characterization (Fig. 1)
MDA-231-derived bCSC were successfully isolated from
both MDA-231 cell–induced xenografts in nude female
mice and from the cultured MDA-231 cells and were
propagated in culture in the form of mammospheres
(MMS) (Fig. 1a). When dissociated into single cells,
mammospheres, with time, formed MMS again. This
process was repeated for many generations and is
considered a sign of self-renewal. These cells exhibited
the characteristic CD44+/CD24-/low phenotype where up to
75% of the cell population stained for this bCSC
phenotype (Fig. 1b).
Effect of CAPE on progenitors and differentiated cells
derived from MMS (Fig. 2)
Single-cell suspensions derived from MMS were treated in
the absence of serum with CAPE at different concentrations
from 0 to 40 μM and, after 4.5 days, viable cells were
counted. CAPE inhibited MMS formation in a dose
dependent manner with a 97% inhibition at 40 μM CAPE
(Fig. 2a). Single-cell suspensions derived from MMS pre-
treated with CAPE for 4.5 days or untreated were seeded at
densities of 800, 400, 200, and 100 cells/well of 96-well
plate in LB-15 containing 5% FBS without CAPE. After
6 days, cell growth was analyzed by MTT assay. In the
absence of CAPE (0 μM), the bCSCs had the ability to
form progenitors and differentiated cells in the presence of
serum (the term progenitors will be used henceforth) and
this ability was cell concentration-dependent with viability
increasing at higher bCSC cell densities. However, progen-
itor formation in the presence of serum was inhibited up to
53% at the highest bCSC density of 800 cells/well at a
CAPE concentration of 20 μM (Fig. 2b).
CAPE effect on MMS growth in soft agar (Fig. 3)
Mammospheres were pre-treated with different concentra-
tions of CAPE for 2 weeks then dissociated into single cells
and equal numbers of viable cells were seeded onto soft
agar for 1 or 4 weeks growth in the presence of serum
(Clones did not grow in agar in the absence of 5% FBS).
CAPE pre-treatment resulted in the inhibition of mammo-
sphere growth in soft agar as seen by decreases in the MMS
sizes as shown in photographs in Fig. 3a. CAPE exhibited
both a dose-dependent and a time-dependent inhibitory
effect with a decline from ~100% clones at 0 μM CAPE
to~18% clones at 40 μM CAPE after 1 week of growth,
and to <5% clones at 40 μM CAPE after 4 weeks of growth
on soft agar (Fig. 3b).
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Effect of CAPE on MMS apoptosis (Fig. 4)
3×104 single cells derived from MMS were cultured
and treated with CAPE for 4.5 days, then incubated
with Annexin V-FITC and propidium iodide (PI) as
described in the Materials and Methods. After 4.5
days, CAPE did not cause apoptosis of bCSCs at
the CAPE concentrations tested (CAPE 20 μM and
40 μΜ).
CAPE effects on cell cycle of MMS (Fig. 5)
3×104 single cells derived from MMS were treated with
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Fig. 2 CAPE inhibits MMS and progenitor formation: CAPE
treatment inhibits MMS growth (without serum, a) and progenitor
formation (with serum, b) in a dose-dependent manner. This inhibition
was statistically significant at 400 cells/well (*p=0.0002) and 800
cells/well (**p=0.004), b The experimental differences were deter-
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R7 -/-   8.3
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CD44
Fig. 1 bCSC isolation and
characterization: bCSC were
isolated from both MDA-231
cells and MDA-231 cell-induced
nude mouse xenografts and
propagated in culture in the
form of mammospheres (MMS)
(a). 75% of these cells exhibited
the characteristic CD44+/CD24-/
low staining (Region 8,
lower-right quadrant) of the
bCSC phenotype (b)
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progression was determined using flow cytometry. MMS
were noted to significantly progress from a typical
quiescent cell cycle state in G0/G1 (82%), S phase (12%)
to a cycling state with an increase in S phase (41%) and
subsequent decrease in G0/G1 (54%).
Changes in MMS phenotype by CAPE (Fig. 6)
Single cells derived from MMS were seeded, cultured and
treated with 40 μM CAPE for 4.5 days as described in
Material and Methods before co-staining with
fluorochrome-conjugated monoclonal antibodies against
human CD44 (APC) and CD24 (PE). CAPE treatment
decreased CD44 levels by ~95%, while another cell
population containing 10 to >100-fold lower CD44 content
concurrently increased.
Discussion
We have previously shown that CAPE inhibits growth of
breast cancer cells, both the estrogen receptor positive as
well as the estrogen receptor negative (TNBC) subtypes
without significant cytotoxic effect on immortalized, but
non-tumorigenic breast cancer cells [36]. Here we show
that CAPE inhibits growth of breast cancer stem cells
(bCSC) isolated from the aggressive triple negative breast
cancer cell line, MDA-231. bCSC were successfully
isolated from both the MDA-231 cell line and MDA-231
cell induced nude mouse xenografts. These cells were
propagated in culture in the absence of serum (Fig. 1a) and
grow as mammospheres (MMS), and when dissociated into
single cells, formed MMS again. This process, considered a
measure of self-renewal, a CSC trait known to be
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Fig. 3 CAPE inhibits mammo-
sphere growth on soft agar:
Single cells derived from CAPE
pre-treated MMS (2 weeks)
were seeded onto soft agar for 1
or 4 weeks in the presence of
serum. CAPE pre-treatment
resulted in a dose-dependent
inhibition of MMS growth on
soft agar (a) as clonal growth
declined from ~100% clones at
0 μM CAPE to~18% clones at
40 μM CAPE (1 week), and
<5% clones at 40 μM CAPE
(4 weeks in agar) (b). Clones of
≥50 cells were counted as one
clone at 1 and 4 weeks in soft
agar. A statistically significant
difference was seen as early as
with a low dose of 5 μM CAPE
(1 week (*p=0.01); and 4 weeks
(**p<0.05). The experimental
differences were determined by
two-tailed Student’s t-test; n=3
and p≤0.05 was taken as a
significant difference
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responsible for regenerating tumor cell mass and cancer
recurrence, was repeated for many generations for 4 weeks.
Further, we demonstrated that the isolated MMS possessed
the identifying characteristics of the CD44+/CD24-/low
phenotype, as assessed by flow cytometry (Fig. 1b). The
MMS population obtained from 4 weeks of self renewal
demonstrated ~75% enrichment of the CD44+/CD24-/low
CSC phenotype, (Fig. 1b).
Cancer stem cells are thought to be more resistant to
chemo- and radiotherapy than non-CSC tumor cells [40],
therefore, agents that interfere with CSC growth could be
potentially highly desirable therapeutic agents. We tested
CAPE’s effect on MMS self renewal in vitro after
incubation with CAPE using different doses (0–40 μM).
Self renewal in the absence of serum was inhibited in a
dose-dependent fashion, with a 97% inhibition at the
highest dose of 40 μM CAPE (Fig. 2a). Further, the ability
to form progenitors in the presence of serum was noted to
be cell concentration-dependent in the absence of CAPE,
while the inhibitory effect after pretreatment with CAPE on
progenitor formation was highest at the cell density of 800
cells/well with about 53% inhibition at 20 μM CAPE
(Fig. 2b). We next examined whether the inhibitory effect
of CAPE on progenitor formation could be recapitulated on
soft agar, typically a measure of malignant potential. We
observed that pretreatment of dissociated MMS with CAPE
at 40 μM resulted in the inhibition of progenitor formation











CAPE 0 M CAPE 40 M
Fig. 5 CAPE promotes cell cycle progression of bCSC: Single cells derived from MMS and treated with 40 μM CAPE shift from a quiescent cell
cycle state in G0/G1 (82%), S phase (12%) to a cycling state with an increase in S phase (41%) and subsequent decrease in G0/G1 (54%)
CAPE 20µM CAPE 40µM
0.1% 1.42% 0.42% 1.70% 1.78%0.46%
40.90% 57.56% 42.48% 55.40% 51.78%45.98%
CAPE 0µM
Fig. 4 CAPE does not cause bCSC apoptosis. CAPE-treated bCSCs for 4.5 days were assessed by Annexin V-FITC (x-axis) and propidium iodide
(PI, y-axis). No increase in Annexin V or PI staining was observed
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inhibitory effect was CAPE dose-dependent with the highest
inhibition at 40 μM CAPE, an effect that was more
pronounced after 4 weeks on soft agar. These results
collectively suggest that CAPE inhibits breast cancer stem
cell self renewal and progenitor formation with associated
inhibitory changes in their inherent malignant potential,
suggesting that CAPE could be a valuable therapeutic agent.
We next sought to determine the basis of this inhibitory
effect of CAPE on MMS growth. First, we examined the
role of apoptosis in CAPE-induced MMS inhibition. CAPE
treatment did not cause MMS apoptosis as determined by
Annexin V/propodium iodide staining (Fig. 4), lending
support to the idea of resistance of CSC to apoptosis from
therapeutic agents. However, CAPE induced a number of
changes in single cells derived from MMS. bCSC isolated
from human tumors are predominantly (75%) in G0/G1
phases [1]. Cell cycle analysis revealed that CAPE-treated
bCSC significantly progressed from a quiescent cell cycle
state in G0/G1 (82%), S phase (12%) to a cycling state with
an increase in S phase (41%) and subsequent decrease in
G0/G1 (54%) (Fig. 5). This apparent contradiction of
findings can be explained by the view that MMS are
usually resistant to killing and cycle very infrequently but,
when they are differentiated to progenitors, cells that cycle,
they become more sensitive to growth inhibition by CAPE.
Under the conditions of our experiments using a CAPE
concentration of 40 μM and defined time of treatment, a
great majority, but not all cell growth is inhibited. Hence,
some differentiated cells are still cycling as shown by flow
cytometry. Actually, differentiation of MMS to progeny and
cell cycling of differentiated cells might be a prerequisite to
the CAPE-mediated observed growth inhibition.
Next, we examined the effects of CAPE on CD44/CD24
expression. Interestingly, we noted changes in the CSC
surface marker characteristics, specifically, CD44, where
CAPE treatment for 4.5 days of dissociated MMS caused
10 to ≥100-fold decrease in CD44 levels, with only ~5% of
high CD44 cell population remaining (Fig. 6). CAPE-
mediated decrease in the levels of CD44, a receptor
important in tumor growth, supports our view described
above that MMS differentiation to progeny and cell












Fig. 6 CAPE results in loss of bCSC phenotype: Incubation with
40 μM CAPE for 4.5 days causes an ~20–25% decline in CD44
density at about the same CD24 levels as those of newly formed
populations due to the MMS+CAPE interaction (a) and ~95% decline
in CD44 levels (comparing the green vs. blue trace) with concurrent
appearance of different cell populations characterized by 10 to ≥100
times lower CD44 density (blue trace) (b)
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the CAPE-induced observed growth inhibition. CD44
supports anchorage-independent growth in vitro and
tumor growth and metastasis in experimental models of
solid cancers [41–44]. CD44 interacts with Hyaluronan
(HA), a major glycosaminoglycan in the extracellular
matrix whose expression is tightly linked to multidrug
resistance and tumor progression [45]. Investigations into
HA-induced interaction between CD44 (an HA receptor)
and Nanog (transcription factor that promotes self renewal and
maintenance of pluripotency in embryonic stem cells) in both
human breast tumor and human ovarian tumor cells reveal that
HA binding to these tumor cells promotes Nanog protein
association with CD44, followed by Nanog activation and the
expression of pluripotent stem cell regulators [45]. Taken
together, targeting HA/CD44-mediated Nanog signaling
pathways and ankyrin/cytoskeleton function may represent
a novel approach to overcome chemotherapy resistance in
breast cancer cells displaying stem cell marker properties
during tumor progression.
Our flow cytometry data indicate that in addition to the
main MMS signal, ~20–25% of bCSC exhibited substantial
decline in CD44 density at about the same CD44 levels as
those of newly formed populations due to the MMS+CAPE
interaction, and about the same CD24 levels, as those
induced by CAPE (Fig. 6a). Further, bCSC incubation with
40 μM CAPE for 4.5 days causes ~95% decline in CD44
levels from that normally present in bCSCs with concurrent
appearance of different cell populations characterized by 10
to ≥100 times lower CD44 density (Fig. 6b). Notably, it
appears that even when MMS are analyzed by flow
cytometry shortly after harvesting, other populations are
already evident. Since the 4.5 day incubation of MMS+CAPE
dose-dependently decreased soft agar growth (Fig. 3b), with
40 μM CAPE inhibiting it by ~95%, it is likely that CD44
decline or a consequence of that decline could be in part
responsible for the inhibition of soft agar growth, a standard
measure of a malignant potential. It is also possible that
effects of CAPE on gene/protein expression and on cell
differentiation could have contributed to this phenomenon.
Furthermore, HA-CD44 interaction induces ankyrin (a
cytoskeletal protein) binding to MDR1 resulting in the
efflux of chemotherapeutic drugs (e.g., doxorubicin and
Taxol) and chemoresistance in these tumor cells [45]. Thus,
the CAPE-induced decline in CD44 could inhibit binding to
MDR1 and the resultant efflux of chemotherapeutic drugs
with a subsequent decrease in chemoresistance of the bCSC.
Additionally, we have previously found that CAPE causes
downregulation of the mdr gene in MDA-231 cells, while a
combination of CAPE and Taxol in vitro and in vivo was
more effective than either of them alone (not shown),
suggesting that CAPE can inhibit efflux of Taxol and be
used as an adjuvant to enhance the therapeutic outcome [36]
(Omene C et al., manuscript in preparation).
To our knowledge, this is the first report of CAPE’s
effects on cancer stem cells, which we show using the
breast cancer model. Collectively, our results suggest that
CAPE causes pronounced changes in breast cancer stem
cell characteristics manifested by inhibition of self renewal,
inhibition of clonal expansion in soft agar, and decrease in
CD44 content, all signs of decreased potential for malignancy.
Further, CAPE induces an increase in the cycling state of the
bCSCs, potentially making them more susceptible to
chemotherapeutic agents if used in combination. Our
results strongly suggest that the MDA-231-derived bCSC
are induced into a less malignant state after CAPE
treatment and may terminally differentiate their progeny
making them more susceptible to chemotherapy. Ongoing
research should reveal the effect of CAPE on bCSC from
other subtypes of breast cancer.
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